When the market's small and the expense for approval is high, companies often don't even bother getting the drug approved in the US. That's what happened to dutasteride, which is approved in the US for use in prostate cancer treatment, but never was recertified for use in fighting male pattern baldness because it would cost too much and the company knows doctor's are prescribing it off label anyway to male pattern baldness patients.
